Synergy Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 2:30 p.m. MST at The Biltmore Hotel in Phoenix, AZ.

A live webcast of Synergy’s presentation will be accessible through the Investors section of the company’s website at www.synergypharma.com. To access the webcast, please log on to the Synergy website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Synergy’s website for approximately 180 days following the conference.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) is a biopharmaceutical company focused on the development of novel therapies to treat gastrointestinal (GI) diseases and disorders. Synergy’s platform technology is based on the naturally occurring human GI hormone, uroguanylin, a key physiological regulator and natural agonist of the intestinal guanylate cyclase-C (GC-C) receptor. Synergy scientists have discovered and developed two unique uroguanylin analogs – plecanatide and SP-333 – designed to mimic uroguanylin’s natural activity on the GC-C receptor and target a variety of GI conditions. Plecanatide is currently in two pivotal phase 3 clinical trials for chronic idiopathic constipation and has successfully completed a phase 2b dose-ranging study in patients with irritable bowel syndrome with constipation. SP-333 is currently in phase 2 development for opioid-induced constipation and is also being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.